Mobile

A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced...

Mise à jour : Il y a 5 ans
Référence : ISRCTN82487767

A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Not provided at time of registration

Critère d'inclusion

  • Topic: Neurological; Subtopic: Neurological (all Subtopics); Disease: Nervous system disorders

Liens